CD40 agonistic-monovalent streptavidin fusion antibody for targeted neoantigen peptide delivery and potent cancer vaccination.
Neoantigen peptides just got a serious delivery upgrade. Researchers at the University of Illinois Chicago and Purdue built a fusion antibody—dubbed αCD40-mSAs—that locks onto CD40 receptors on antigen-presenting cells, then shuttles biotinylated peptides right where they need to go. These CD40-targeted fusion proteins take the guesswork out of getting cancer vaccine payloads to the immune system’s command centers.
J Control Release
by Jung D, Cai X, Wan Z et al.
“CD40 agonistic-monovalent streptavidin fusion antibody for targeted neoantigen peptide delivery and potent cancer vaccination. Jung D(1), Cai X(1), Wan Z(1), Khalil EA(1), Lee N(2), Ramseier NT(3), Bao Q(1), Zhao Z(4), Hu Y(5), Lim SO(6), Lee SS(7). Author information: (1)Department of Pharmaceutical Sciences, Retzky College of Pharmacy, University of Illinois Chicago, Chicago, IL, USA. (2)Borch Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN, USA. (3)Department of Chemistry, University of Illinois Chicago, Chicago, IL, USA. (4)Department of Pharmaceutical Sciences, Retzky College of Pharmacy, University of Illinois Chicago, Chicago, IL, USA; University of Illinois Cancer Center, University of Illinois Chicago, Chicago, IL, USA. (5)Department of Chemistry, University of Illinois Chicago, Chicago, IL, USA; University of Illinois Cancer Center, University of Illinois Chicago, Chicago, IL, USA; Department of Biomedical Engineering, University of Illinois Chicago, Chicago, IL, USA. (6)Borch Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN, USA. Electronic address: limsoe@purdue.edu. (7)Department of Pharmaceutical Sciences, Retzky College of Pharmacy, University of Illinois Chicago, Chicago, IL, USA; University of Illinois Cancer Center, University of Illinois Chicago, Chicago, IL, USA; Department of Biomedical Engineering, University of Illinois Chicago, Chicago, IL, USA. Electronic address: ssylee@uic.edu. Cancer vaccines targeting patient-derived neoantigens offer great promise for personalized cancer therapy but face challenges in achieving targeted delivery to antigen-presenting cells (APCs) to elicit robust and durable cancer-specific immune responses. To address this, we developed an anti-mouse CD40 agonistic-monovalent streptavidin fusion antibody (αCD40-mSAs) that targets CD40, a key stimulatory receptor on APCs, to deliver biotinylated neoantigen peptides directly to APCs in draining lymph nodes (dLNs). We confirmed mSA expression on the engineered antibody and its strong binding affinities to mouse CD40 and biotin. Advanced microscopy demonstrated that αCD40-mSAs enhance homing to dLNs and the intracellular delivery of neoantigen peptides to critical APC subsets, such as conventional type 1 dendritic cells (cDC1s). Effective intracellular co-delivery of αCD40-mSAs and neoantigen peptides primarily drove enhanced dendritic cell (DC) activation and antigen presentation. In vivo vaccination with peptide-loaded αCD40-mSAs elicited robust cancer-specific CD8+ T cell responses, leading to significant tumor regression and prevention in mouse tumor models. These results support αCD40-mSAs as a multifunctional vaccine delivery platform with immunopharmacological advantages by combining targeted delivery and immune stimulation in a single engineered antibody system. Our approach addresses major limitations of current cancer vaccine strategies and provides a modular platform with strong translational potential for personalized cancer immunotherapy. Copyright © 2026 The Author(s). Published by Elsevier B.V. All rights reserved. Conflict of interest statement: Declaration of competing interest Authors declare that they have no competing interests.”
Here’s the core move: the antibody binds to mouse CD40 (a stimulatory receptor on APCs) and also to biotin, snagging any biotinylated peptide you want. The team showed this fusion protein homes in on draining lymph nodes, dumping its peptide cargo directly into key dendritic cell subsets like cDC1s. The result is more efficient loading, better antigen presentation, and—most importantly—a much stronger CD8+ T cell response in mouse tumor models.
Why care? Because personalized cancer vaccines live or die by how well you get those custom peptides into APCs. Most current approaches struggle with poor targeting and weak immune activation. This platform solves both. You get targeted peptide delivery AND immune stimulation in a single, modular system.
Key details:
αCD40-mSAs combine antibody precision with a biotin-peptide catch mechanism
Delivers peptides right into lymph node APCs, especially cDC1s
Triggers robust cancer-specific T cell responses in vivo
Tumor regression and prevention observed in mouse models
This isn’t just another antibody tweak. It’s a flexible delivery engine for the whole category of neoantigen-based peptide vaccines. The modular design means you can swap in any biotinylated peptide sequence—potentially streamlining personalized cancer immunotherapy.
For anyone tracking the next wave of peptide-based vaccine tech, this is worth a closer look. Check out the peptide research index for more on related breakthroughs. The future of targeted cancer vaccination is getting sharper, one peptide at a time.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.